Clinical Trials

A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy in Patients With Unresectable or Me

Cancer Type

Colorectal Cancer

ClinicalTrials.gov Identifier

ClinicalTrials.gov registration not required

Principal Investigator

Sukeshi Patel Arora, MD

For more information about this study
View Details

About This Study

This is a Phase 1b/2, randomized, multicenter, open-label study to investigate the efficacy and safety of LBL007 plus tislelizumab in combination with bevacizumab plus capecitabine, or LBL-007 in combination with bevacizumab plus capecitabine versus bevacizumab plus capecitabine, in PD-L1 positive and negative population respectively (Arm A versus Arm C in PD-L1 positive population group, and Arm D versus Arm E in PD-L1 negative population group), as maintenance therapy in patients with unresectable or metastatic MSS/pMMR CRC.